S H Kelkar & Company LtdQ1 FY27
S H Kelkar & Company Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹154P/E: 50.0Market Cap: ₹2.4K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
Yes
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- →The company targets double-digit revenue growth for FY 2027, with some quarterly variations expected due to geopolitical and demand timing factors.
- →Flavours segment achieved Rs. 112 crore in Q1, with a normalized run rate estimated around Rs. 95-96 crore from Q2 onwards; growth expected to be strong but not at Q1 levels due to inventory prepayments.
- →Fragrance segment sees growth opportunities, especially in new markets like Europe (Germany), USA, and UK, with expected breakeven in 3 years and subsequent fast growth.
- →New initiatives in Europe and the USA show traction, aiming for $100 million market capture over next few years.
- →Investments in R&D and CDCs to support sustained growth and product innovation.
- →Overall growth constrained by macroeconomic stability; stable environment critical for doubling revenue in 5 years.
- →EBITDA margins expected to improve with revenue scale-up and fixed cost absorption as investments mature.
Margin guidance
Category 3- →The company targets double-digit revenue growth for FY2027, expecting margins to improve if growth sustains.
- →Flavour business displayed strong Q1 performance (Rs. 112 crore), anticipated to normalize to Rs. 95-96 crore per quarter going forward, with Q2 expected stronger than Rs. 95 crore.
- →Fragrances & Ingredients businesses are expected to catch up through the year, with investments in R&D and global CDCs likely to impact margins temporarily.
- →New market bets in Germany, USA, and UK aim for EBITDA breakeven by year 3 post-investment; Germany expected to break even between this year and next.
- →Long-term target ROCE is 20%, with 15% ROCE expected in 3-5 years as new initiatives ramp up.
- →Stable macroeconomic environment is critical to achieving revenue doubling over five years.
- →EBITDA margins likely to improve due to operating leverage and completed capex cycle.
3 more insights locked — sign up free to unlock
Fundraise plans
No- →No plans for significant new fundraising through debt in the near term.
- →Debt level expected to remain broadly at the current June 2026 level, with a slight increase possible in September 2026.
- →From Q3 FY27 onwards, management expects to start reducing debt by approximately Rs. 25 crore quarter-on-quarter.
- →The company is focused on deleveraging in the medium to long term despite ongoing capex and strategic inventory buildup.
- →No mention of raising equity funding during the call.
Order book
Yes- →In Q1 FY 2027, there was a higher-than-expected sales number in the Flavours segment, partly due to client preponement and extra stock buildup (approx. Rs. 15 crore).
- →This Rs. 15 crore reflects additional inventory rather than final consumption.
- →The base regular orderbook for Flavours is estimated around Rs. 95-97 crore per quarter.
- →Going forward, Q2 and subsequent quarters are expected to normalize with Flavours around Rs. 95-96 crore, potentially slightly higher but not at the Q1 level of Rs. 112 crore.
- →No new segments or large global account orders are currently significant.
- →Business remains normal with double-digit growth overall.
- →USA and UK markets are at early stages; expected minimum revenue from USA is Rs. 1.5 to 2 million for the year.
- →Germany is progressing well with regular traction.
- →No major breakthroughs with global accounts at present, especially in Flavours; new product adoption typically takes 3-4 years to mature.
Capex plans
Yes- →Completed European capex with the plant operational since May; Rs. 25 crore spent in Europe in Q1 FY27.
- →Ongoing capex in India focusing on Vanvate and Vashivali fragrance projects; Rs. 25 crore planned for Vanvate in Q2 and approximately Rs. 50 crore remaining for three plants in India.
- →Vanvate factory expected to be operational by Q3 FY27.
- →Decision pending on whether the remaining Rs. 25 crore for Vashivali plant upgradation will be spent in Q4 FY27 or deferred to next year.
- →The company is investing roughly $3 million annually in R&D to support growth.
- →Capital deployment reflects strategic inventory buildup and capacity expansion to capture growth opportunities in Europe, USA, and UK.
- →Medium to long-term focus on deleveraging after completing capex cycle.
How does S H Kelkar & Company Ltd rank vs peers in Chemicals & Petrochemicals?
Pro feature1S H Kelkar & Company Ltd
Rev 3Mar 3
See full Chemicals & Petrochemicals sector rankings
How does S H Kelkar & Company Ltd rank in Chemicals & Petrochemicals?
Compare S H Kelkar & Company Ltd against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.